profit from every $100 of sales.
$0$100
Minerva Neurosciences
$2.56+2.81% today
-35.5% in 1 year
1-year low $2.201-year high $8.07
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Minerva Neurosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$293 million of profit last year.
SalesProfit
Minerva Neurosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Minerva Neurosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Minerva Neurosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -25 | -23 | -22 | -15 | |
| -25 | -22 | 6 | -293 | |
| -32 | -30 | 1 | -293 | |
| -6.01 | -4.61 | 0.19 | -34.67 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 55 | 57 | 37 | 98 |
| Cash | 36 | 41 | 21 | 82 |
| Total debt | – | – | – | – |
| Total liabilities | 75 | 85 | 63 | 239 |
| -20 | -28 | -26 | -141 | |
| 5 | 7 | 8 | 8 | |
| – | – | – | – | |
| 160.3% | 105.4% | -5.6% | 208.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -25 | -15 | -20 | -14 | |
| 0 | – | – | – | |
| -25 | -15 | -20 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 2 | 1 | 1 |
Valuation
- –
- –
- –
- -1.0×
- –
- –
- –
- -10,590.3%
- -230.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -31.1%
- 4.3%
- 108,955.4%
- -133,678.5%
- -31.1%
- –
Growth
- –
- –
- −69,007.6%
- –
- +12.2%
Financial health
- -0.0×
- -0.26
- 69.1%
- –
- 17.65
- 17.65
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 14%of 958
Bottom 21%of 888
What analysts expect
- Average price target
- $5.00
- Range
- $5.00 – $5.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.17 | -0.13 | −30.8% |
| Mar 11, 2026 | -0.64 | -0.11 | −481.8% |
| Nov 5, 2025 | -0.36 | -0.35 | −2.9% |
| Aug 14, 2025 | -0.43 | -0.95 | +54.7% |
| May 13, 2025 | -0.50 | -1.07 | +53.3% |
| Feb 25, 2025 | -0.56 | -1.05 | +46.7% |
| Nov 5, 2024 | 2.97 | -1.01 | +394.1% |
| Aug 6, 2024 | -1.09 | -0.97 | −12.4% |
News
Nvidia launches Minerva AIOps platform for AI factory observabilityYahoo Finance · Oct 23, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/5Passes 0 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
–Not enough data
Philip Fisher
30No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
25No pass
Questions about Minerva Neurosciences
Is Minerva Neurosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Minerva Neurosciences AI analysis
What does Minerva Neurosciences do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. It is in Biotechnology.
Does Minerva Neurosciences pay a dividend?
No. Minerva Neurosciences does not pay a dividend at the moment.
Is Minerva Neurosciences stock halal?
No. Minerva Neurosciences does not pass our halal screen: its debt is 51% of its market value, at or above the 33% limit. How we check
How has Minerva Neurosciences stock done over the past year?
Down 35.5% over the past twelve months, to $2.56. It traded between $2.20 and $8.07 and is 68.3% below its high.
Who are Minerva Neurosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Minerva Neurosciences's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.